证券代码：301239 证券简称：普瑞眼科 公告编号：2023-054 成都普瑞眼科医院股份有限公司 在使用闲置募集资金暂时补充流动资金期间，公司严格遵守《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等相关法律、法规 和规范性文件的要求，对募集资金进行了合理的安排与使用，用于暂时补充流动 资金的闲置募集资金仅用于与主营业务相关的生产经营，资金使用安排合理，不 影响募集资金投资项目的正常实施，不存在与募集资金投资项目的实施计划相抵 触的情形，亦不存在变相改变募集资金投向和损害股东利益的情形。 2023年7月11日，公司将用于暂时补充流动资金的闲置募集资金5,000万元提 前归还至募集资金专用账户，使用期限未超过12个月，具体内容详见公司于2023 年7月11日在巨潮资讯网披露的《关于提前归还部分暂时补充流动资金的闲置募 集资金的公告》（公告编号：2023-047）。 公司于近日将剩余用于暂时补充流动资金的闲置募集资金25,000万元提前 归还至募集资金专用账户，使用期限未超过12个月，并就上述归还事项及时通知 了公司 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2023-052 成都普瑞眼科医院股份有限公司 关于签订房屋租赁合同补充协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、租赁房产事项及进展 成都普瑞眼科医院股份有限公司（以下简称"公司"）于2022年9月19日召 开第二届董事会第二十四次会议审议通过了《关于公司拟签订房屋租赁合同的 议案》，同意公司拟承租深圳国贸天安物业有限公司（以下简称"国贸天安"） 位于深圳市罗湖区人民南路3012号天安国际大厦1-4层裙楼建筑物为公司经营所 在地，并与国贸天安签署《房屋租赁合同》，租赁期限20年，自2023年8月1日 起至2043年7月31日止，租赁期间全部租赁费用为人民币41,448.24万元。具体 内容详见公司于2022年9月21日在巨潮资讯网（www.cninfo.com.cn）披露的公 司《关于公司拟签订房屋租赁合同的公告》。公司已与国贸天安签署《房屋租 赁合同》（以下简称"原合同"）。 近日，经双方友好协商一致，公司与国贸天安签署了《房屋租赁补充协 议》，约定将免租期延长五个月。 甲方：深圳国 ...

证券代码： 301239 证券简称：普瑞眼科 成都普瑞眼科医院股份有限公司投资者关系活动记录表 编号：2023-006 | 投资者关系活动 | 分析师会议 □特定对象调研 □ | | | --- | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | | □ 新闻发布会 □ 路演活动 | | | | □ 现场参观 | | | | 其他 （请文字说明其他活动内容） □ | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 年 月 日 (周二) 下午 2023 5 15:00~17:00 | 9 | | 地点 | 网络远程 | | | 上市公司接待人 | 董事长：徐旭阳 | | | 员姓名 | 副总经理、董事会秘书：金亮 | | | | 财务负责人：杨国平 | | | | 独立董事：汤华东 | | | | 保荐代表人：朱玉峰 1、请问公司为何不像华夏眼科一样定个目标，每年增长 30%以 上？希望公司在并购或新开医院的时候要认真考察，请问公司有 | | | | 没有具体人员负责，过程能否做到廉洁，还有希望公司能送股， 以利公司做大做强，谢谢！ | ...

Financial Performance - The company's main business revenue has declined, particularly in mature hospitals in cities like Kunming, Chengdu, Wuhan, and Chongqing, with a slowdown in revenue and profit growth compared to the previous year[27]. - Management expenses and sales expenses as a percentage of operating income increased in 2022 compared to 2021, leading to a decline in overall profit[5]. - The net profit for the year significantly decreased due to complex domestic and international economic conditions and shrinking demand, despite the company's efforts to maintain stable operations[28]. - The financial report indicates a notable decrease in non-operating income, with other non-recurring gains and losses recorded at approximately ¥381,980[19]. - The company's total revenue for 2022 was approximately ¥1.73 billion, representing a year-on-year increase of 0.91%[47]. - Net profit attributable to shareholders decreased by 78.09% to CNY 20,568,200.89[64]. - The net profit after deducting non-recurring gains and losses was CNY 18,538,023.18, down 78.36% year-on-year[64]. - The gross profit margin for the medical sector was 41.65%, reflecting a decrease of 1.72% compared to the previous year[48]. Market Outlook - The company anticipates that the ophthalmic medical service industry will return to normal development as the economy gradually recovers, with previous investments and cost reduction efforts expected to yield results in the future[28]. - The Chinese ophthalmic medical service market is projected to reach RMB 223.1 billion by 2024, with a compound annual growth rate (CAGR) of 11.05% from 2020 to 2024[43]. - The number of myopic patients in China increased from 540 million in 2016 to 660 million in 2020, with the overall myopia rate rising from 39.2% to 47.1%[43]. - The cataract surgery market is expected to grow as awareness increases, with the incidence rate of cataracts in the population aged 60-89 at 80%[43]. Business Development - The company has established 24 chain ophthalmology specialty hospitals and is in the process of preparing several new hospitals, which are expected to drive future growth[45]. - The company is enhancing its medical technology and quality by recruiting renowned experts and improving medical quality management systems[45]. - The company is focusing on high-end surgical methods and multifunctional intraocular lenses to meet the quality demands of middle-aged and elderly patients[45]. - The company aims to improve its bargaining power with suppliers through scale expansion and centralized procurement, thereby reducing costs and increasing gross margin[45]. - The company has established a new regional division in the Greater Bay Area to enhance management efficiency and is focusing on this area as a key growth engine[46]. - The company is implementing a "national chain + local integration" strategy to enhance revenue growth potential[65]. Operational Efficiency - The company has completed organizational adjustments and optimizations to strengthen operational support across its national layout, which has resulted in increased personnel costs[5]. - The company has launched a stable and efficient HCRM system, currently operational in 9 hospitals, to improve management efficiency and service quality[58]. - The company aims to enhance its digital transformation and accelerate the construction of a digital development system[124]. - The company plans to enhance its data decision-making capabilities by accelerating the construction of a data center platform and integrating various digital systems[1]. Research and Development - Research and development investment amounted to ¥6,644,826.66, which is 0.39% of the operating revenue for 2022[83]. - The company is investing heavily in R&D, with a budget allocation of 100 million for new technologies and innovations[157]. - The company aims to establish a comprehensive medical education and research innovation system to promote product and service technology upgrades[148]. Governance and Management - The company has appointed new board members and management, including a new general manager, to strengthen governance and leadership[140]. - The governance structure has been enhanced to comply with regulatory standards, ensuring no significant discrepancies exist[156]. - The company is actively involved in the nomination process for board members and senior management, ensuring a robust governance structure[181]. - The company has established a clear decision-making process for the remuneration of directors, supervisors, and senior management, ensuring transparency and accountability[193]. Social Responsibility and Compliance - The company is actively responding to national calls and fulfilling corporate social responsibilities while focusing on strategic goals to enhance management efficiency[28]. - The company emphasizes maintaining high-quality medical services to mitigate risks associated with medical accidents[127]. - The company recognizes the potential impact of regulatory changes in the healthcare sector and is committed to adapting its strategies accordingly[151]. Customer and Market Engagement - The company has launched a member points mall to enhance member benefits and loyalty, providing various products and services for redemption[58]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users[157]. - Major customers accounted for 6.86% of total annual sales, with the largest customer contributing 3.24%[51]. Financial Management - Cash flow from financing activities was CNY 1,038,322,980.00, a decrease of 2,445.05% compared to the previous year[58]. - The net increase in cash and cash equivalents was CNY 755,455,302.40, down 760.79% year-on-year[58]. - The company has a strong emphasis on internal controls and risk management, as highlighted by the independent director's expertise in these areas[186].

Financial Performance - The company's revenue for Q1 2023 was ¥649,826,753.50, representing a 38.73% increase compared to ¥468,422,199.36 in the same period last year[12]. - Net profit attributable to shareholders reached ¥162,393,315.01, a significant increase of 334.85% from ¥37,345,056.26 year-over-year[12]. - The basic earnings per share (EPS) was ¥1.09, up 230.30% from ¥0.33 in the previous year[12]. - The company's operating revenue for the reporting period was RMB 649.83 million, an increase of 38.73% compared to the previous period, primarily due to the expansion of new hospitals and increased sales scale[29]. - Net profit for the current period was ¥165,334,547.22, representing a substantial increase of 44.73% compared to ¥37,345,056.26 in the previous period[57]. - The company reported a basic and diluted earnings per share of ¥1.09, up from ¥0.33 in the previous period[57]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,129,697,823.92, reflecting a 12.31% increase from ¥3,676,965,643.95 at the end of the previous year[12]. - The total liabilities amounted to RMB 1.88 billion, compared to RMB 1.61 billion in the previous period[21]. - The total equity attributable to the parent company was RMB 2.23 billion, compared to RMB 2.07 billion in the previous period[21]. - Cash and cash equivalents at the end of the period totaled ¥932,964,231.47, up from ¥113,604,394.24 at the beginning of the period, reflecting a net increase of ¥6,734,399.75[51]. - The total assets at the end of the period reached $4.13 billion, up from $3.68 billion, indicating a growth of 12.2%[61]. - Non-current assets totaled $2.69 billion, up from $2.49 billion, representing an increase of 8.0%[61]. Cash Flow - The net cash flow from operating activities was ¥120,447,583.12, a slight decrease of 2.10% from the previous year[12]. - The net cash flow generated from operating activities was RMB 120.45 million, a decrease of 2.10% compared to the previous period, mainly due to increased costs[29]. - The net cash flow from operating activities was $120.45 million, slightly down from $123.03 million, a decrease of 2.1%[62]. - Cash outflow from investing activities was $209.01 million, compared to $265.09 million, showing a reduction of 21.1%[62]. - Cash inflow from financing activities was $182.80 million, down from $202.50 million, a decrease of 9.8%[62]. Expenses - Research and development expenses increased by 206.26% to ¥2,211,400.00, primarily due to increased spending on ophthalmology-related clinical applications and digital research[14]. - The company's management expenses for the reporting period were RMB 76.63 million, an increase of 12.42% compared to the previous period, primarily due to increased salaries and depreciation expenses[29]. - Total operating costs amounted to ¥549,611,128.83, up 30.94% from ¥419,861,898.34 in the prior period, primarily driven by a 40.04% increase in operating costs due to sales growth[38][59]. Acquisitions and Investments - The company completed the acquisition of 80% equity in Dongguan Guangming Eye Hospital[18]. - The company completed the acquisition of a 35% stake in Dongguan Guangming Eye Hospital, increasing its total ownership to 80%[45]. - The company's investment income for the reporting period was RMB 92.05 million, an increase of RMB 86.18 million compared to the previous period, mainly due to the revaluation of equity in Dongguan Guangming Eye Hospital[29]. Other Financial Metrics - The weighted average return on equity (ROE) improved to 7.56%, up from 3.86% in the previous year[12]. - The company experienced a 73.81% increase in taxes payable, primarily due to an increase in corporate income tax[14]. - The income tax expense for the current period was ¥23,978,782.96, a 46.39% increase from ¥16,379,916.00 in the previous period, mainly due to the increase in total profit[55]. - Other income increased to ¥2,418,412.98 from ¥1,646,244.94 in the previous period, indicating improved financial performance[38]. - The balance of goodwill at the end of the reporting period increased by 1440.08% compared to the beginning of the period, due to the conversion of an originally affiliated company into a non-same control enterprise[29]. - The balance of contract liabilities at the end of the reporting period increased by 45.07% compared to the beginning of the period, attributed to business scale growth[29]. - The balance of other payables at the end of the reporting period increased by 197.87% compared to the beginning of the period, due to increased operating expenses[29].

证券代码：301239 证券简称：普瑞眼科 公告编号：2023-039 成都普瑞眼科医院股份有限公司 关于举行2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院股份有限公司（以下简称"公司"）于2023年4月26日在 巨潮资讯网（www.cninfo.com.cn）披露公司《2022年年度报告》全文及摘要。 为便于广大投资者更加全面深入地了解公司经营管理情况，公司将于2023年5月 9日（星期二）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩 说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：公司董事长徐旭阳先生，独立董事汤华东 先生，副总经理兼董事会秘书金亮先生，财务负责人杨国平先生，保荐代表人 朱玉峰先生。 为进一步做好中小投资者保护工作，增进投资者对公司的了解，现就公司 2022年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议，提升交流效率和针对性。投 ...

Group 1: Company Overview - Panyu Puri Eye Hospital officially opened in August 2022, with an area of approximately 6,000 square meters, designed and equipped according to the standards of a tertiary eye hospital [2][3] - The hospital has signed a medical insurance agreement with the Medical Insurance Bureau in January 2023, marking a significant operational milestone [2][3] Group 2: Medical Services and Equipment - Panyu Puri offers four major specialties: pediatric eye diseases and optometry, refractive surgery, cataract specialty, and comprehensive eye disease specialty, staffed by experts primarily from Zhongshan University Eye Center [3][4] - The hospital is equipped with advanced medical devices, including CLARUS 500 ultra-widefield fundus camera, IOLmaster 700, and CIRRUS HD-OCT 5000, ensuring high-quality medical services [3][4] Group 3: Market Analysis - Panyu has a resident population of nearly 2.8 million, with a total population close to 4 million, indicating a strong market potential for eye care services [3][4] - The local eye care market is characterized by a lack of resources and uneven distribution, with the largest public hospital in the area not generating significant revenue relative to the population size [3][4] Group 4: Strategic Planning - Puri Eye plans to focus on the Greater Bay Area for future investments, having established a dedicated division for this region [4][5] - The company has completed site selection for new hospitals in Guangzhou and Shenzhen, with expectations to open by the end of 2023 or early 2024 [4][5] Group 5: Financial Projections - Panyu Puri anticipates achieving profitability within three years, with strong operational performance driven by expert resources and advanced equipment [5][6] - Prior to the medical insurance agreement, approximately 90% of revenue came from non-insured services, primarily refractive surgery [5][6] Group 6: Competitive Landscape - The eye care market in Guangzhou is large, with significant competition from both public and private institutions, including the leading Zhongshan University Eye Center [5][6] - Despite competition, the overall market penetration remains low, suggesting opportunities for growth through resource integration and operational efficiency [6][7]